REGULATORY
Shionogi’s Novel Antibiotic Fetroja Gets Fast-Track Listing for Dec. 20
A key Japanese reimbursement policy panel has agreed to add Shionogi’s siderophore cephalosporin antibiotic Fetroja (cefiderocol) approved late last month to the NHI price list on December 20. The Central Social Insurance Medical Council (Chuikyo) approved the fast-track listing of…
To read the full story
Related Article
- Shionogi’s Novel Antibiotic Fetroja Now Available in Japan
December 21, 2023
REGULATORY
- MHLW Orders Label Revisions for Remicade, Enbrel, Bavencio, and More Drugs
April 22, 2026
- Extra Charges Likely for OTC-Like Drugs to Treat Seasonal Conditions: Minister
April 22, 2026
- Japan Panel to Review Boehringer’s IPF Drug, Moderna COVID Shot on April 27
April 21, 2026
- Ferring Gene Therapy, Fujifilm Cell Product Inch Closer to Approval
April 21, 2026
- Japan Launches Panel to Promote Radiopharmaceuticals
April 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





